Life Tech Unveils CastPCR TaqMan Assays for Cancer Mutation Detection
April 07, 2011
Life Tech Unveils CastPCR TaqMan Assays for Cancer Mutation Detection
The mutation detection assays for KRAS, BRAF, and EGFR genes are based on competitive allele-specific TaqMan PCR. The company claims the assays are sensitive enough to detect single mutant molecules in a background of 1 million normal copies.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Life Tech Expands CastPCR Mutation Detection Assays to Include 21 Additional Cancer Genes
April 5, 2012 / PCR Insider - IP Watch: Recent Patents Related to PCR, Nucleic Acid Amplification, and Sample Prep
May 31, 2011 / PCR Insider - Life Tech Developing CastPCR Method to Detect Rare Tumor Cells in FFPE Tissue, Blood
September 16, 2010 / PCR Insider - Life Tech Commercializes Low-cost Digital PCR System; Stem Cell Characterization Assay
June 13, 2013 / PCR Insider - IP Watch: Hologic, Roche, Qiagen, Life Tech, Alere, Genaphora, Others Win US Patents
June 11, 2013 / PCR Insider